---
layout: default
title: Vinpocetine
parent: 僅模型預測 (L5)
nav_order: 1061
evidence_level: L5
indication_count: 10
---

# Vinpocetine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Vinpocetine: From Cerebrovascular Disease to Coronary Artery Disease

## One-Sentence Summary

> Vinpocetine is a PDE1 inhibitor whose pharmacology has been studied mainly in the context of cerebrovascular disease and cognitive impairment.
> The TxGNN model predicts it may also be effective for **Coronary Artery Disease**,
> but this direction is currently supported only by **0 clinical trials** and **3 publications**, all preclinical, mechanistic, or narrative-review in nature.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not formally documented in the evidence pack; associated literature frames vinpocetine's pharmacology around cerebrovascular disease/cerebral hypoperfusion |
| Predicted New Indication | Coronary Artery Disease |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 (preclinical/mechanistic + review only) |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for vinpocetine is not available from DrugBank in this evidence pack (data gap). However, the indication-specific rationale supplied alongside the prediction describes vinpocetine as a **PDE1 (phosphodiesterase-1) inhibitor** that increases intracellular cAMP/cGMP, producing vasodilation, improved hemodynamics, and anti-inflammatory effects via NF-κB inhibition. This pharmacology has historically been explored in cerebrovascular and cerebral hypoperfusion contexts.

Coronary artery disease and cerebrovascular disease share overlapping vascular/ischemic pathophysiology (endothelial dysfunction, impaired microcirculation, atherosclerosis-related hypoperfusion), which is the conceptual basis for TxGNN's cross-indication prediction. However, the supplied rationale itself flags this extrapolation as **mechanistically weak**: none of the available evidence directly addresses coronary pathology such as plaque burden or luminal stenosis, and the literature instead centers on cerebral blood flow and general vascular hemodynamics.

A related predicted indication in this evidence pack — *myocardial ischemia* (rank 2, evidence level L3) — has somewhat stronger support, including small observational studies and an animal myocardial infarction model, and may be a more promising angle for the same underlying mechanistic hypothesis than coronary artery disease specifically.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [17631470](https://pubmed.ncbi.nlm.nih.gov/17631470/) | 2007 | Review | Orvosi hetilap | Discusses vinpocetine's role in cerebrovascular disease treatment; notes coronary artery disease and cancer as leading causes of death exceeding cerebrovascular disease, and highlights the benefit of increasing cerebral blood flow in chronic hypoperfusion |
| [15377497](https://pubmed.ncbi.nlm.nih.gov/15377497/) | 2005 | Preclinical/Mechanistic | Am J Physiol Lung Cell Mol Physiol | Isoform-selective PDE inhibitors (PDE3/PDE4, related mechanistic class) potentiate prostacyclin analog effects on pulmonary vascular remodeling in vitro/in vivo — indirect mechanistic support for PDE-pathway vascular effects |
| [3188457](https://pubmed.ncbi.nlm.nih.gov/3188457/) | 1988 | Cohort (small, pre-modern era) | Vrachebnoe delo | Early (pre-modern) study of kavinton (vinpocetine) effects on hemodynamics and adenosine metabolism in atherosclerosis patients; no abstract data available for detailed findings |

---

## Singapore Market Information

Vinpocetine currently holds **no marketing authorization in Singapore** (0 registered licenses; market status: not marketed). No product-level regulatory data (dosage form, approved indication) is available for review.

---

## Safety Considerations

Please refer to the package insert for safety information. No verified warnings, contraindications, or drug-drug interaction data are currently available in this evidence pack — this is flagged as a **Blocking** data gap (DG001: TFDA/HSA label warnings and contraindications not yet retrieved), which must be resolved before any safety assessment can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The coronary artery disease prediction is supported only by preclinical/mechanistic and narrative-review literature (Evidence Level L4) with no clinical trials, no direct evidence of efficacy in coronary pathology, and an explicitly flagged mechanistic gap in the rationale itself. Combined with the absence of any Singapore market presence and a blocking safety data gap, this candidate does not yet meet the threshold to proceed.

**To proceed, the following is needed:**
- Retrieve HSA/TFDA label warnings and contraindications (resolve DG001, currently Blocking)
- Obtain formal DrugBank mechanism-of-action data (resolve DG002)
- Seek direct preclinical or clinical evidence linking vinpocetine to coronary artery pathology (not just general vascular/cerebrovascular hemodynamics)
- Consider evaluating the related "myocardial ischemia" prediction (L3, stronger observational and animal-model support) as an alternative or complementary research direction
- Confirm route of administration compatibility once regulatory/product data becomes available
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

